GSK (LON:GSK) Insider Luke Miels Sells 15,579 Shares of Stock

GSK plc (LON:GSK) insider Luke Miels sold 15,579 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of GBX 2,160, for a total value of £336,506.40.

Luke Miels also recently made the following trade(s):

• On Monday, February 9th, Luke Miels sold 4,549 shares of GSK stock. The stock was sold at an average price of GBX 2,211, for a total value of £100,578.39.

GSK Price Performance

GSK opened at GBX 2,239 on Wednesday. The business has a fifty day moving average of GBX 1,897.25 and a 200 day moving average of GBX 1,708.84. The stock has a market cap of £90.34 billion, a P/E ratio of 16.83, a PEG ratio of 1.24 and a beta of 0.31. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. GSK plc has a 52-week low of GBX 1,242.50 and a 52-week high of GBX 2,260.

GSK (LON:GSK) last posted its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, sell-side analysts anticipate that GSK plc will post 175.980975 EPS for the current year.

Analysts Set New Price Targets

GSK has been the topic of several research reports. Berenberg Bank raised their price target on GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a research note on Monday, November 24th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a report on Thursday, January 15th. Citigroup increased their price objective on shares of GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research note on Monday, February 9th. UBS Group reissued a “neutral” rating and set a GBX 1,940 price objective on shares of GSK in a report on Friday, January 23rd. Finally, JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Wednesday, January 7th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, GSK presently has an average rating of “Hold” and a consensus price target of GBX 1,917.86.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.